Together we will beat cancer

Donate

Around 47,700 men are diagnosed with prostate cancer in the UK each year, making it the most common cancer in men in the UK. It develops in the prostate, a walnut-sized gland found at the base of the bladder.

Olaparib approved for 800 prostate and breast cancer patients in England

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

Read More

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

Read More

Advanced MRI could help to differentiate aggressive and slower growing prostate cancer

New research has found that using an advanced MRI technique may enable doctors to pinpoint potentially aggressive or fast-growing cancers and guide treatment pathways.

Read More

Targeted prostate cancer screening: Are we there yet?

Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?

Read More

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

Read More

Investigating suspected prostate cancer: Improving GP-patient communication

A study published earlier this year uncovered some important differences in people’s experience of visiting the GP.

Read More

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

Read More

Hormone therapy gets green light for advanced prostate cancer

Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option.

Read More

The (un)usual suspects – how early detection research embraces interdisciplinary science

Meet two of the latest Primer Awardees and find out why forensic science and nanomaterials are, in fact, ideal backgrounds for cancer research

Read More

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

Read More